InDex Pharmaceuticals has received conditional approval from Nasdaq Stockholm for the continued listing of its shares, following its acquisition of Flerie Invest AB as part of a strategic transformation.

Information on the Target

InDex Pharmaceuticals Holding AB, a publicly traded company based in Stockholm, has announced a conditional approval from Nasdaq Stockholm for the continued listing of its shares on the Nasdaq First North Growth Market. This approval is part of the company's strategy to implement a reverse acquisition of Flerie Invest AB, which is expected to significantly transform its operations.

On May 20, 2024, InDex Pharmaceuticals signed a conditional agreement to acquire all shares of Flerie Invest AB. Following this transaction, InDex will rename itself to Flerie AB (New Flerie), and Flerie will become a wholly-owned subsidiary of InDex. The shift in business strategy necessitated the application for continued listing approval from Nasdaq, reflecting the complete integration of Flerie's business into InDex's operational framework.

Industry Overview in Sweden

The pharmaceutical industry in Sweden is known for its strong position in research and development, heavily driven by innovation and collaboration between academ